Table 9.
Cancer nanomedicine Polymeric Nanoparticles formulation in the treatment or management of breast cancer.
| Brand Name | Therapeutic Agent | Clinical Trial Phase | Company Name | Reference |
|---|---|---|---|---|
| NCT00629499 P | Paclitaxel/Cyclophosphamide | Phase II | SCRI DevelopmentInnovations, LLC | [119] |
| NCT04249167 | Cryoablation, atezolizumab/nab-paclitaxel | Early Phase I | Mayo Clinic | [120] |
| NCT03606967 | Paclitaxel and durvalumab with or without neoantigen vaccine | Phase II | National Cancer Institute (NCI) |
[121] |
| NCT00407888 | Doxorubicin hydrochloride, cyclophosphamide, and filgrastim followed by paclitaxel | Phase II | University of Washington |
[122] |
| NCT00616967 | Carboplatin and nab-paclitaxel with or without vorinostat |
Phase II | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
[123] |